ICWEA Statement on Gilead Sciences’ Licensing of Lenacapavir: A Step Toward Expanding HIV Prevention Choices

The International Community of Women Living with HIV Eastern Africa (ICWEA) welcomes Gilead Sciences' decision to license the production and sale of the generic version of Lenacapavir to six pharmaceutical…

Continue ReadingICWEA Statement on Gilead Sciences’ Licensing of Lenacapavir: A Step Toward Expanding HIV Prevention Choices

ICWEA Statement on Gilead’s announcement of twice-yearly Lenacapavir (LEN) for HIV prevention.

The International Community of Women Living with HIV Eastern Africa (ICWEA) celebrates Gilead's recent announcement regarding the twice-yearly Lenacapavir (LEN), which has demonstrated 100% efficacy and superiority over daily Truvada…

Continue ReadingICWEA Statement on Gilead’s announcement of twice-yearly Lenacapavir (LEN) for HIV prevention.